CUE
Income statement / Annual
Last year (2025), Cue Biopharma Inc's total revenue was $27.47 M,
an increase of 195.75% from the previous year.
In 2025, Cue Biopharma Inc's net income was -$26.60 M.
See Cue Biopharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$27.47 M |
$9.29 M |
$5.49 M |
$1.25 M |
$14.94 M |
$3.15 M |
$3.46 M |
$1.14 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.48 M
|
$0.00
|
$38.10 M
|
$0.00
|
-$1.78 M
|
$33.55 M
|
$27.49 M
|
$28.54 M
|
$419.57 K
|
$202.09 K
|
| Gross Profit |
$23.99 M
|
$9.29 M
|
-$32.61 M
|
$1.25 M
|
$16.72 M
|
-$30.39 M
|
-$24.03 M
|
-$27.40 M
|
-$419.57 K
|
-$202.09 K
|
| Gross Profit Ratio |
0.87
|
1
|
-5.94
|
1
|
1.12
|
-9.63
|
-6.95
|
-23.98
|
0
|
0
|
| Research and Development Expenses |
$37.74 M
|
$36.30 M
|
$40.80 M
|
$38.58 M
|
$41.35 M
|
$33.55 M
|
$27.49 M
|
$28.54 M
|
$18.90 M
|
$5.69 M
|
| General & Administrative Expenses |
$16.24 M
|
$14.59 M
|
$16.68 M
|
$16.17 M
|
$17.31 M
|
$14.65 M
|
$11.78 M
|
$11.30 M
|
$4.33 M
|
$1.97 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$965.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.24 M
|
$14.59 M
|
$16.68 M
|
$16.17 M
|
$17.31 M
|
$14.65 M
|
$12.74 M
|
$11.30 M
|
$4.33 M
|
$1.97 M
|
| Other Expenses |
-$3.48 M
|
-$93.00 K
|
-$37.94 M
|
-$277.00 K
|
$1.78 M
|
-$33.55 M
|
-$27.49 M
|
$165.34 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$50.51 M
|
$50.79 M
|
$19.54 M
|
$54.47 M
|
$60.43 M
|
$14.65 M
|
$12.74 M
|
$39.84 M
|
$23.23 M
|
$7.66 M
|
| Cost And Expenses |
$53.99 M
|
$50.79 M
|
$57.64 M
|
$54.47 M
|
$58.65 M
|
$48.20 M
|
$40.23 M
|
$39.84 M
|
$23.23 M
|
$7.66 M
|
| Interest Income |
$807.00 K
|
$1.62 M
|
$2.66 M
|
$928.24 K
|
$45.90 K
|
$463.91 K
|
$419.00 K
|
$376.01 K
|
$35.00
|
$52.00
|
| Interest Expense |
$357.00 K
|
$796.00 K
|
$1.25 M
|
$713.82 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.48 M
|
$2.35 M
|
$3.44 M
|
$1.81 M
|
-$1.78 M
|
$1.06 M
|
$810.78 K
|
$760.01 K
|
$419.57 K
|
$202.09 K
|
| EBITDA |
-$23.04 M |
-$37.53 M |
-$46.05 M |
-$50.49 M |
-$45.44 M |
-$43.99 M |
-$35.96 M |
-$37.94 M |
-$22.81 M |
-$7.46 M |
| EBITDA Ratio |
-0.84
|
-4.04
|
-8.39
|
-40.56
|
-3.04
|
-13.94
|
-10.4
|
-33.2
|
0
|
0
|
| Operating Income Ratio |
-0.97
|
-4.47
|
-9.5
|
-42.75
|
-2.93
|
-14.28
|
-10.63
|
-33.87
|
0
|
0
|
| Total Other Income/Expenses Net |
$419.00 K
|
$826.00 K
|
$1.42 M
|
$215.00 K
|
$45.90 K
|
$463.91 K
|
$482.79 K
|
$541.35 K
|
$35.00
|
$52.00
|
| Income Before Tax |
-$26.10 M
|
-$40.67 M
|
-$50.73 M
|
-$53.01 M
|
-$43.67 M
|
-$44.58 M
|
-$36.29 M
|
-$38.16 M
|
-$23.23 M
|
-$7.66 M
|
| Income Before Tax Ratio |
-0.95
|
-4.38
|
-9.24
|
-42.58
|
-2.92
|
-14.13
|
-10.49
|
-33.39
|
0
|
0
|
| Income Tax Expense |
$500.00 K
|
$0.00
|
$0.00
|
$0.00
|
$495.00 K
|
$206.25 K
|
$412.50 K
|
$825.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$26.60 M
|
-$40.67 M
|
-$50.73 M
|
-$53.01 M
|
-$44.16 M
|
-$44.78 M
|
-$36.70 M
|
-$38.98 M
|
-$23.23 M
|
-$7.66 M
|
| Net Income Ratio |
-0.97
|
-4.38
|
-9.24
|
-42.58
|
-2.96
|
-14.2
|
-10.61
|
-34.12
|
0
|
0
|
| EPS |
-8.4 |
-21.6 |
-33.3 |
-44.7 |
-42.3 |
-46.8 |
-49.8 |
-58.2 |
-33.9 |
-11.1 |
| EPS Diluted |
-8.4 |
-21.6 |
-33.3 |
-44.7 |
-42.3 |
-46.8 |
-49.8 |
-58.2 |
-33.9 |
-11.1 |
| Weighted Average Shares Out |
$3.16 M
|
$1.88 M
|
$1.53 M
|
$1.19 M
|
$1.04 M
|
$956.29 K
|
$734.73 K
|
$671.14 K
|
$688.02 K
|
$688.02 K
|
| Weighted Average Shares Out Diluted |
$3.16 M
|
$1.88 M
|
$1.53 M
|
$1.19 M
|
$1.04 M
|
$956.29 K
|
$734.73 K
|
$671.14 K
|
$688.02 K
|
$688.02 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
